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Abstract
Objectives: multiple myeloma is a malignant neoplasm of plasma cells mainly affecting elderly patients. Despite the wealth
of information available on therapeutic strategies, the etiology and pathogenesis of myeloma remain unclear. In the current
study, a meta-analysis was conducted to assess the possible association between rheumatoid arthritis and myeloma.
Methods: a literature search was conducted with PubMed, EMBASE and Web of Science for relevant studies published by
December 25, 2013. Additionally, we searched annual meeting abstracts of the American Society of Hematology from 2004
to 2013. Only original studies that investigated the association between rheumatoid arthritis and myeloma were included. In
total, 8 case-control and 10 cohort studies were identified for analysis.
Results: the meta-estimate of the association between rheumatoid arthritis and myeloma was 1.14 (95% CI, 0.97–1.33)
overall, with significant heterogeneity among studies. The relationship between myeloma and other autoimmune diseases
was additionally examined from available data. Our results showed that myeloma risk is increased 1.31 to 1.65-fold in
pernicious anemia and 1.36 to 2.30-fold in ankylosing spondylitis patients.
Conclusion: Rheumatoid arthritis does not appear to alter the risk of myeloma, while between-study heterogeneity analyses
suggest caution in the interpretation of results. Pernicious anemia and ankylosing spondylitis may be potential risk factors
for myeloma development. Future large-scale epidemiological studies with reliable exposure biomarkers are necessary to
establish the possible contribution of autoimmune disorders to multiple myeloma.
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Introduction
Multiple myeloma (MM) is one of the most common
hematologic malignancies with poor prognosis, characterized by
neoplastic proliferation of monoclonal plasma cells. The incidence
of MM in developed countries is about 5–7 cases per 100 000
individuals [1]. Despite extensive research efforts over the last two
decades, the risk factors of MM remain to be established.
Numerous case-control and cohort studies to date have suggested
that several environmental factors may be associated with the risk
of MM, such as ionizing radiation [2], benzene [3] and
agricultural occupation [4]. The relationship between autoim-
mune disease and hematopoietic malignancies was initially
postulated in 1964 [5]. However, the issue of whether autoim-
mune diseases increase the incidence of MM remains controver-
sial.
On the basis of animal models of MM, it is suggested that
repeated antigenic stimulation of the immune system plays an
important role in MM development [6,7]. A number of studies
have confirmed an association of lymphoma with autoimmune
conditions [8–12], including rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE), and autoimmune hemolytic anemia,
although the underlying pathogenesis is unclear. Similarly, the
relationship between MM and autoimmune disease has been a
long-term subject of investigation, but inconsistent results have
been obtained to date.
The main aim of this meta-analysis was to estimate the
comparative risk of developing MM in RA patients versus the
general population. Two additional goals were (1) to explore the
variation in the association of RA and MM among subgroups of
interest and (2) to investigate if there is an association between
MM and other autoimmune diseases.
Methods
Search Strategy
A literature search was conducted with PubMed (from January
1, 1951), EMBASE (from January 1, 1955) and Web of Science
(from January 1, 1970) using the following search terms:
rheumatoid arthritis, autoimmune disease, etiology, epidemiology,
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risk factors, multiple myeloma, cancer, malignancy. The final
search strategy in PubMed was attached as appendix. The last
literature search was performed on December 25, 2013. We also
searched annual meeting abstracts of the American Society of
Hematology from 2004 to 2013 to identify eligible unpublished
data. All references cited in the retrieved articles were additionally
reviewed to indentify additional eligible studies. Inclusion criteria
were as follows: human participants without limitation of sex or
geographic location, case-control or cohort studies, prior medical
history of RA as exposure, MM as outcome, studies that reported
relative risk (RR), standardized incidence ratio (SIR) or odds ratio
(OR) of MM patients with prior history of RA, publication in
English. In addition, the selection of cohort studies for inclusion
was made regardless of specific RA management strategies. When
duplicate reports for the same population and data source were
eligible, we chose the original reports with the largest sample size.
Case series, case reports, in vitro and animal studies were
excluded. Eligibility assessment was performed independently by
two reviewers, and disagreements resolved by consensus.
Data Extraction
Two authors performed data extraction independently, and any
discrepancies were addressed by discussion and re-evaluation. We
obtained information on the author, year of publication, country
of origin, source of case, control and cohort, controlled factors,
diagnosis criteria and treatment regimen for RA. Cohort size,
number of cases, cohort duration, SIR and 95% confidence
intervals (CIs) or sufficient data to allow calculation of these
numbers were additionally necessary for cohort studies. For case-
control studies, the exact numbers of cases and controls by RA,
OR and 95% CIs were required. For the purpose of ascertaining
the relationship between MM and other autoimmune diseases,
related data were recorded, where available, according to the
above extraction principles.
The Newcastle-Ottawa Scale (NOS), developed for evaluating
the quality of nonrandomized studies [13], was used by two
independent reviewers to assess the methodological quality of each
study, and the scores subsequently used in subgroup analysis. A
score of #5 was considered as relative low quality [14].
Statistical Analyses
In case-control studies, OR and 95% CIs for MM risk factors
were directly extracted from original research papers or calculated
when not provided. The primary outcome for cohort studies was
SIR and corresponding 95% CI. In cases where SIRs were not
specifically reported, calculations were made from the number of
observed MM divided by the number of expected cases in the
general population provided by authors, and 95% CI determined
using the standard error of the natural logarithm of SIR, estimated
from the inverse of the square root of the observed number of
cases. The measure of interest was RR, estimated from ORs in
case-control studies and SIRs in cohort studies. Since the
incidence of MM is low, SIR and OR produce similar estimate
of RR, thus we present all results as RR for simplicity [15–17].
Between-study heterogeneity was examined using a chi-square test
of heterogeneity and I2 measure of inconsistency. P-values less
than 0.1 or the I2 statistic greater than 50% were considered
statistically significant [18]. Under these conditions, data were
pooled based on the method of Dersimonian and Laird under a
random effects model otherwise under fixed effects model. Two-
tailed p#0.05 was considered statistically significant for all
analyses.
To evaluate publication bias, we constructed a funnel plot and
applied Begg’s test. Trim and Fill analysis was used to estimate the
number of missing studies and their potential effects on outcomes.
Sensitivity analyses were additionally conducted to ascertain the
robustness of our findings. The influence of RA was examined by
excluding studies restricted to elderly patients ($65 years) or
Figure 1. Flow diagram depicting the identification and selection of eligible case-control and cohort studies.
doi:10.1371/journal.pone.0091461.g001
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single-sex participants and those that failed to control important
confounders. All meta-analyses were conducted with Stata 12.0.
Results
Abstract evaluation yielded thirty-two potential studies for
analysis (Figure 1), of which five [19–23] were excluded, since they
Figure 2. Forest plot of studies on multiple myeloma development risk in rheumatoid arthritis.
doi:10.1371/journal.pone.0091461.g002
Table 3. Sensitivity analysis of the association between multiple myeloma and rheumatoid arthritis according to different
exclusion criteria.
Studies included Studies (N) RR (95% CI) p value I2 (%)
All studies 18 1.14 (0.97–1.33) ,0.001 71.5
Studies without age restriction of participantsa 17 1.09 (0.94–1.27) ,0.001 68.7
Studies with both male and female participantsb 15 1.11 (0.94–1.32) ,0.001 74.1
Studies that controlled for important confounding factorsc 16 1.11 (0.95–1.30) ,0.001 73.1
aExcludes the study by the group of Setoguchi [41].
bExcludes studies by the groups of Pearce [25], Landgren [36] and Brown [45].
cExcludes studies by the groups of Pearce [25] and Landgren [36].
Abbreviations: N, number; RR, relative risk; NS, not significant; CI, confidence interval.
doi:10.1371/journal.pone.0091461.t003
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failed to provide sufficient data for calculation. Twenty-three case-
control and cohort studies were included after full text assessment.
Another two publications [24,25] were incorporated after exam-
ining references from the extracted articles. Among the 25 studies,
seven [12,26–31] were subsequently excluded for overlap in case
or cohort resources. Consequently, our meta-analysis consisted of
eight [24,25,32–37] case-control and ten [10,38–46] cohort
studies.
All the studies published from 1982 to 2013 were performed in
USA or Europe, except one case- control study from New Zealand
[25]. There was slight overlap in the patient populations of two
studies [38,40] from Finland. Landgren et al. [36] limited the
study subjects to women, while the groups of Pearce [25] and
Brown [45] mainly focused on the role of prior autoimmune
disorders in male MM. The NOS scores varied from 5 to 7 in all
case-control studies, with the exception of the reported score of 3
by Landgren and co-workers [36] as a result of unsatisfactory
comparability. Since almost all the cohort studies used the
expected cancer incidence calculated from national cancer rates
as a comparison instead of the non-exposed cohort, NOS scores
were relatively low, ranging from 4 to 5.
In the eight case-control studies, OR was all obtained from the
published articles or calculated from the numbers of cases and
controls by RA. In four cohort studies [10,38,43,44], the SIRs and
95% CIs were estimated from the number of observed MM and
expected MM incidence provided by authors, while others were
directly extracted from the original article. Only three studies
[41,42,44] reported the type of treatment for RA before MM
diagnosis. All important information is presented in Tables 1 and
2.
Table 4. Meta-analysis of multiple myeloma incidence by subgroup.
Subgroup Analyses (N) RR (95% CI) p-value I2 (%)
Overall Study design Cohort (10) 1.32 (1.04–1.67) ,0.001 72.9
Case-control (8) 0.92 (0.77–1.11) 0.031 54.6
Publication year Before 2000 (7) 1.10 (0.77–1.59) ,0.001 75.7
After 2000 (11) 1.15 (0.96–1.37) ,0.001 71.3
Study quality NOS#5 (13) 1.29 (1.02–1.64) ,0.001 72.7
NOS.5 (5) 0.95 (0.79–1.14) 0.024 64.3
Regiona USA (9) 1.02 (0.86–1.22) 0.008 61.4
Europe (8) 1.30 (0.93–1.79) ,0.001 80.9
Cohort Publication year Before 2000 (3) 1.48 (0.90–2.45) 0.047 67.3
After 2000 (7) 1.25 (0.96–1.61) 0.002 72.0
Study quality NOS#5 (9) 1.36 (1.02–1.81) ,0.001 75.9
NOS.5 (1) 1.17 (0.94–1.45) – –
Region USA (4) 1.25 (0.89–1.77) 0.017 70.4
Europe (6) 1.37 (0.95–1.97) ,0.001 77.7
Mean follow-upb ,5 years (5) 1.63 (0.97–2.74) ,0.001 80.4
$5 years (4) 1.17 (0.82–1.66) 0.015 71.2
Case-control Publication year Before 2000 (4) 0.81 (0.65–1.02) 0.352 8.1
After 2000 (4) 1.02 (0.77–1.36) 0.021 69.1
Study quality NOS#5 (4) 1.14 (0.71–1.83) 0.060 59.5
NOS.5 (4) 0.88 (0.71–1.10) 0.046 62.5
Regiona USA (5) 0.91 (0.74–1.11) 0.116 45.9
Europe (2) 1.28 (0.41–3.96) 0.033 77.9
Control type Population (6) 0.92 (0.78–1.10) 0.088 47.8
Hospital (2) 1.22 (0.34–4.36) 0.023 80.6
Abbreviations: N, number; M, male; F, female; RR, relative risk; NOS, Newcastle-Ottawa Scale.
aOne case-control study conducted in New Zealand was excluded from analysis.
bOne study with unknown mean follow-up duration was excluded from analysis.
–: Cannot be calculated.
doi:10.1371/journal.pone.0091461.t004
Figure 3. Funnel plot for case-control and cohort studies (dots:
original data; squares: filled data).
doi:10.1371/journal.pone.0091461.g003
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The RRs of MM for RA versus non-RA patients overall and by
study design was presented (Figure 2). The random-effects pooled
RRs for MM were 1.32 (95% CI, 1.04–1.67) for cohort studies and
0.92 (95% CI, 0.77–1.11) for case-control studies. Compared with
non-RA patients, RA patients showed an RR of 1.14 (95% CI,
0.97–1.33) regardless of study type, possibly suggesting lack of
association between RA and MM. However, overall analysis
revealed significant between-study heterogeneity (p,0.1;
I2 = 71.5%).
Sensitivity analysis was presented in Table 3. After excluding
studies restricted to elderly patients ($65 years) or single-sex
participants and those that failed to adjust important factors,
overall RR decreased slightly to 1.09, 1.11 and 1.11, respectively.
To investigate the source of heterogeneity, subset analysis by
study design, publication year, study quality, geographic region,
control type and average follow-up duration was conducted.
Statistical association between RA and MM was only found to be
significant in studies with relatively low quality (RR=1.29, 95%
CI, 1.02–1.64) and cohort studies with relatively low quality
(RR=1.36, 95% CI, 1.02–1.81). Overall, in studies with relatively
higher quality according to NOS, as well as those published after
2000, RA was not associated with increase in MM risk (RR=0.95,
95% CI, 0.79–1.14 and RR=1.15, 95% CI 0.96–1.37, respec-
tively). Notably, subgroup analyses failed to define the reason for
heterogeneity (Table 4).
Publication bias in this meta-analysis was suspected as indicated
from the funnel plot and Begg’s test (p = 0.081). However, RR
values remained similar after Trim and Fill correction for possible
missing data (RR=1.14, 95% CI 0.97–1.33 before Trim and Fill
versus RR=1.09, 95% CI 0.93–1.27 after Trim and Fill)
(Figure 3).
The reported relevance of other autoimmune diseases, including
pernicious anemia and ankylosing spondylitis (AS), in MM
incidence is presented (Figure 4). Patients with pernicious anemia
and AS displayed a 1.31- to 1.65-fold and 1.36- to 2.30-fold
increase in MM risk, respectively. In contrast, MM development
appeared to be unrelated to prior medical history of psoriasis
(RR=0.91, 95% CI, 0.78–1.05), SLE (RR=1.18, 95% CI, 0.88–
1.60), Sjo¨gren syndrome (SS) (RR=1.22, 95% CI 0.83–1.78) or
polymyositis/dermatomyositis (RR=1.37, 95% CI 0.86–2.17).
The between-study heterogeneity analyses were all not statistically
significant.
Discussion
Our meta-analysis results suggest that MM seems not more
common in patients with a past history of RA, consistent with our
sensitivity data. However, subgroup analysis revealed that RA
patients are more likely to suffer from subsequent MM in cohort
studies (RR=1.32, 95% CI 1.04–1.67). Information on prior
autoimmune diseases in case-control studies was mostly obtained
from self-reports through interviews or questionnaires, while in
cohort studies, investigators relied mainly on linkage records,
which probably attributed to the differences between the two types
of studies. Notably, subset analysis confirmed that statistical
association between RA and MM was only significant in studies
with NOS score#5, further indicating that RA might not act as
risk factor for MM.
A number of studies have explored whether repeated or chronic
antigenic stimulation leads to hematopoietic malignancies. Some
researchers [31] reported elevated risk for MM in patients with
RA, while others [47,48] reached different conclusions. An
Figure 4. Forest plot of studies on multiple myeloma development risk in pernicious anemia and AS.
doi:10.1371/journal.pone.0091461.g004
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antigenic stimulation hypothesis was proposed to explain the
excessive risk of MM in patients with autoimmune diseases.
Chronic immune stimulation resulting from autoimmune disor-
ders, with its associated lymphocyte activation, tends to induce
uncontrolled proliferation of malignant plasma cells, leading to
MM [49]. Since no biologic marker has been developed that can
effectively measure lifetime immune stimulation, this theory
remains controversial. Meanwhile, evidence from previous studies
indicates that increased risk could be a consequence of therapy,
rather than the disease itself. For instance, higher risk of non-
Hodgkin’s lymphoma and MM has been reported following use of
steroids [36,50], which are important for autoimmune disease
treatment. Similarly, cytotoxic and immunosuppressive drugs may
suppress immunodefense against malignant cells and lead to
oncogenesis [51]. Moreover, there may be a common genetic or
environmental susceptibility in autoimmune diseases and plasma
cell tumors, or undiagnosed MM may manifest with clinical
features that mimic connective tissue diseases. Taking our current
results and the above studies into account, the credibility of the
antigenic stimulation hypothesis is called into question.
Only one cohort study [39] investigated the effect of the
duration of follow-up on the risk of MM and determined that the
borderline excess of MM was confined to the early 4-year follow-
up. Thomas [10] proposed that although increased risk of MM
persisted for hematopoietic cancers throughout the follow-up
period, the greatest excess was within the first 3 months after
hospitalization. These findings could possibly indicate a common
etiologic factor for RA and MM, or further prove the association
confirmed in above two studies might be resulted from detection
bias. With the current common application of anti-TNF drugs,
concern has been raised about the risk of developing malignancy
related with their use [52]. However, as implied from two studies
mentioned earlier [41,44], there was no significant increase in the
risk of MM among anti-TNF users. Considering the small number
of reports available, further studies are warranted to account for
this potential confounder when examining the relationship of
autoimmune diseases and MM.
Meta-analysis results revealed that pernicious anemia is another
risk factor for MM, consistent with several prior epidemiologic
studies [53,54]. The related pathogenesis may involve immune
alterations or chromosome abnormalities in the bone marrow of
patients with pernicious anemia [54]. On the other hand, vitamin
B12 deficiency caused by pernicious anemia may promote MM
development by disrupting normal homeostasis for one-carbon
metabolism [55]. The lack of association of MM with psoriasis,
SLE, SS, and polymyositis/dermatomyositis raises the question of
whether oncogenesis is dependent on the type of autoimmune
disease. A number of studies evaluating the risk of MM in AS [45]
and polymyalgia rheumatic [37] patients have reported positive
associations, similar to our assessment of AS and MM. Assump-
tions such as whether an autoimmune disease resulting in MM is
associated with disease activity, amount of autoantibody, and the
extent of organ involvement should be examined. Although the
current meta-analysis presents a more precise estimate of MM risk
in RA patients than individual studies, significant heterogeneity
remains a primary limitation of our study. Subgroup analyses
failed to determine the source of heterogeneity. The diversity of
subject sources and study methodologies may have led to
inconsistencies. One such example is the study by Boffetta [33]
including 282 patients that died from MM, meaning that they
were likely to suffer from more severe diseases and past medical
history obtained from their family members was possibly
incomplete. Similarly, another study [41] was restricted to subjects
older than 65 years whose disease spectrum may be distinct from
that of the general population. The variable proportions of races in
different studies may additionally contribute to significant hetero-
geneity. Moreover, misclassification of patients may have occurred
in case-control studies, since no consistent diagnosis criteria were
applied by investigators and most enrollments were dependent on
reports and certificates, rather than specific laboratory data,
similar to enrollment in cohort studies. As indicated in cohort
studies, RA patients may develop MM after more than 20 years, in
which case recall bias may exist in case-control studies.
Another limitation of this study is that certain articles had to be
excluded, since no data on MM and RA were available, although
their relationship was evaluated. Exclusion of such studies may
have led to results bias. In spite of this, the possible bias might not
be so evident, since why these data were not reported mostly lied
in that authors found no specific association between RA and
MM. Although publication bias was borderline significant as
indicated by Begg’s test, adjustment for possibly missing manu-
scripts yielded similar results, strongly supporting the robustness of
our analyses.
Conclusion
Despite its limitations, our meta-analysis provides novel
evidence for increased MM development risk in AS and pernicious
anemia, although the underlying pathogenesis remains controver-
sial. Notably, RA does not appear to alter the risk of MM, while
between-study heterogeneity suggested caution in the interpreta-
tion of results. Further large-scale longitudinal studies containing
details of risk factors and treatment information are necessary to
determine the pathophysiological mechanism linking autoimmune
diseases and MM. Moreover, identification of reliable exposure
biomarkers of immune stimulation would be significantly benefi-
cial.
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